Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
B cells and multiple sclerosis.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Drug Safety Labeling Changes
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Natalizumab Use During the Third Trimester of Pregnancy.
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Oligodendrocyte death results in immune-mediated CNS demyelination.
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)

Pages